Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model
Karen E. Parrish, Jenny L. Pokorny, Rajendar K. Mittapalli, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 355, Iss. 2, pp. 264-271
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

Revisiting the role of ABC transporters in multidrug-resistant cancer
Robert W. Robey, Kristen M. Pluchino, Matthew D. Hall, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 7, pp. 452-464
Open Access | Times Cited: 1518
Renal Drug Transporters and Drug Interactions
Anton Ivanyuk, Françoise Livio, Jérôme Biollaz, et al.
Clinical Pharmacokinetics (2017) Vol. 56, Iss. 8, pp. 825-892
Closed Access | Times Cited: 199
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Debarati Ghosh, Saikat Nandi, Sonali Bhattacharjee
Clinical and Translational Medicine (2018) Vol. 7, Iss. 1
Open Access | Times Cited: 192
Understanding and targeting resistance mechanisms in cancer
Zi‐Ning Lei, Tian Qin, Qiu‐Xu Teng, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 117
Nanomedicine for brain cancer
Sabina Quader, Kazunori Kataoka, Horacio Cabral
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114115-114115
Open Access | Times Cited: 100
LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation
Yan-wen Liu, Rui Xia, Kai Lǚ, et al.
Molecular Cancer (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 160
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Timothy P. Heffron
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 22, pp. 10030-10066
Closed Access | Times Cited: 121
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Silvia Paola Corona, Daniele Generali
Drug Design Development and Therapy (2018) Vol. Volume 12, pp. 321-330
Open Access | Times Cited: 119
Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2
Mark C. de Gooijer, Nienke A. de Vries, Tessa Buckle, et al.
Neoplasia (2018) Vol. 20, Iss. 7, pp. 710-720
Open Access | Times Cited: 106
Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities
Donglu Zhang, Cornelis E. C. A. Hop, Gabriela Patilea-Vrana, et al.
Drug Metabolism and Disposition (2019) Vol. 47, Iss. 10, pp. 1122-1135
Open Access | Times Cited: 105
ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas
David Gomez‐Zepeda, Méryam Taghi, Jean‐Michel Scherrmann, et al.
Pharmaceutics (2019) Vol. 12, Iss. 1, pp. 20-20
Open Access | Times Cited: 100
Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies
Jun Wang, Alexandra Garancher, Vijay Ramaswamy, et al.
Annual Review of Neuroscience (2018) Vol. 41, Iss. 1, pp. 207-232
Open Access | Times Cited: 97
Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models
Michelle L. Cook Sangar, Laura A. Genovesi, Madison W. Nakamoto, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 19, pp. 5802-5813
Open Access | Times Cited: 94
Current Approaches for Glioma Gene Therapy and Virotherapy
Kaushik Banerjee, Felipe J. Núñez, Santiago Haase, et al.
Frontiers in Molecular Neuroscience (2021) Vol. 14
Open Access | Times Cited: 77
The influence of the blood–brain barrier in the treatment of brain tumours
Sneha Rathi, Jessica I. Griffith, Wenjuan Zhang, et al.
Journal of Internal Medicine (2022) Vol. 292, Iss. 1, pp. 3-30
Closed Access | Times Cited: 41
Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
Mikhail V. Blagosklonny
Oncotarget (2023) Vol. 14, Iss. 1, pp. 193-206
Open Access | Times Cited: 35
Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches
Dev Kumar Tripathy, Lakshmi Priya Panda, Suryanarayan Biswal, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 14
Advances in the Repurposing and Blood–Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors
Julian S. Rechberger, Stephanie Toll, Subhasree Biswas, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 439-439
Open Access | Times Cited: 1
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Inan Olmez, Breanna Brenneman, Aizhen Xiao, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 22, pp. 6958-6968
Open Access | Times Cited: 86
Contraction of T cell richness in lung cancer brain metastases
Aaron S. Mansfield, Hongzheng Ren, Shari L. Sutor, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 80
Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies
Ranjeet Prasad Dash, R. Jayachandra Babu, Nuggehally R. Srinivas
European Journal of Drug Metabolism and Pharmacokinetics (2017) Vol. 42, Iss. 6, pp. 915-933
Closed Access | Times Cited: 77
Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine
Minjee Kim, Sani H. Kizilbash, Janice K. Laramy, et al.
Pharmaceutical Research (2018) Vol. 35, Iss. 9
Open Access | Times Cited: 74
Combination of palbociclib and radiotherapy for glioblastoma
Shane Whittaker, Daniel Madani, Swapna Joshi, et al.
Cell Death Discovery (2017) Vol. 3, Iss. 1
Open Access | Times Cited: 73
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
Shiv K. Gupta, Emily J. Smith, Ann C. Mladek, et al.
Frontiers in Oncology (2019) Vol. 8
Open Access | Times Cited: 71
The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors
Mark C. de Gooijer, Ping Zhang, Ruud Weijer, et al.
International Journal of Cancer (2017) Vol. 142, Iss. 2, pp. 381-391
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top